- Republican Wins Money Race in New York Special
- Congressional Hits and Misses: Week of April 20, 2015
- Pelosi Reacts to Death of Al Qaida Hostages
- Pelosi Calls Emerging Trade Deal a 'Pothole'
- Freshman's Campaign Issue Gets D.C. Attention
The Pharmaceutical Research and Manufacturers of America is continuing the makeover of its executive ranks with the appointment of Chip Davis, a former drug company executive, to the newly created position of executive vice president of advocacy.
Davis will oversee PhRMA’s federal, state and international relations and advocacy efforts, according to a Thursday press release, which added that he will report to the association’s new CEO and president, John Castellani. Previously, the various departments now under Davis’ control reported to different people.
PhRMA, one of the most influential and top-spending lobbying groups in Washington, D.C., has undergone major changes at the top this year with the resignation of its former president, former Rep. Billy Tauzin (R-La.), who played a key role in mobilizing support for this year’s health care reform law.
Since April, Davis has been PhRMA’s acting senior operating officer, appointed to help with the transition when Tauzin announced his departure. At the time, Davis was on a leave of absence from his position as vice president of corporate external relations for AstraZeneca Pharmaceuticals.
“Chip Davis has been invaluable during our transition process, providing steady leadership and guidance,” Castellani said in a statement. Castellani, the former president of the Business Roundtable, was hired by PhRMA in July.
At AstraZeneca, Davis oversaw the drug company’s government relations division and was the chief liaison to PhRMA. David Brennan, AstraZeneca’s CEO, was chairman of PhRMA in 2009 through this spring.
Davis has an undergraduate degree in accounting from the University of Delaware and a law degree from the University of Baltimore School of Law.
In the release, Davis said that he was “excited to join PhRMA permanently to work with John and the terrific people in the organization to further our industry’s efforts to advance sound policies that recognize the value of medical innovation and ensuring patient access to medicines.”